Journal
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Volume 51, Issue 7, Pages 606-614Publisher
DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CP201800
Keywords
tacrolimus; liver transplantation; population pharmacokinetics; model; covariates; clinical practice
Categories
Funding
- Universidad del Pais Vasco scholarships [GIU09/15, UFI 11/23]
Ask authors/readers for more resources
Aim: To determine how changes in tacrolimus (TAC) immunosuppression clinical practice, in the first 15 days post liver transplantation (LT) and across a decade, impact a clinical covariate - pharmacokinetic (PK) model, developed in data from 1998, thus testing its utility in dose individualization across time. Patient cohorts from 1998 (Reference: R-1998) and 2007 (Evaluation: E-2007) were compared. Methods: Analysis of monitoring observations (C-min and C-min/dose) and the biochemical variables aspartate aminotransferase (AST), hematocrit (HCT), albumin (ALB) and serum creatinine (SCr) was done for 0 - 3 and 4 - 15 days post transplantation (PT). The population PK model developed for R-1998 [1] was re-evaluated for the two cohorts. Results: Significant differences in R-1998 vs. E-2007 existed in C-min and C-min/dose and in covariates AST (as hepatic function marker) and SCr (as toxicity marker). E-2007 had lower levels of C-min and C-min/dose (1/CL), lower AST with faster recovery and lower variability in C-min/dose for similar dose. AST was a covariate on CL/F in the 0 3 day PT period. In 4 - 15 days PT for E-2007, low levels of HCT and ALB as CL/F predictors confirmed a subgroup with higher CL/F (23.8 1/h vs. 19.3 1/h). The R-1998 model's original structure was confirmed. Conclusions: Ten years of use of TAC shows gain in therapeutic targeting efficiency, due to improvement in LT methods, knowledge of the drug and consideration of PK steady state. The remaining uncertainty with TAC monitoring in LT can be resolved with application of PK principles combined with patients' idiosyncrasies in the model developed for TAC dose individualization in R-1998. The applicability of the model as nucleus in Bayes individualization remains intact across a decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available